PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $31.64M (cash outflow) rose 27.9% year over year, ahead of the +13.6% change in trailing-twelve-month net income. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Net income amounted to 31.0% of revenue in FY2025, down 9.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$95.57M (-0.0%) for the fiscal year ending Dec 2026, a slowdown from the +4.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$31.64M+6.0% QoQ
- Last fiscal yearDec 2025
- -$95.57M+4.5% YoY
- LTMMar 2026
- -$102.47M+13.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.9% | +35.2% | +7.3 pp |
| 1 year | +4.5% | -0.0% | -4.6 pp |
| 3-year CAGR | +3.1% | -20.1% | -23.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (95.57M) USD
- Year-over-year change
- -4.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.57M) | -4.5% |
| FY2024 | 2024-12-31 | (91.41M) | +13.7% |
| FY2023 | 2023-12-31 | (105.9M) | -21.5% |
| FY2022 | 2022-12-31 | (87.15M) | -45.6% |
| FY2021 | 2021-12-31 | (59.85M) | — |
Net Income vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 net income of $102.47M is the largest of the 5 companies compared; the peer median is $17.73M.
- Its year-over-year change of +13.6% is the 3rd highest of 4, against a peer median of +21.8%.
- Net income amounts to 31.8% of revenue for PRCT, versus a peer median of 51.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.47M | +13.6% | +3.1% | 31.8% | |
| LTM Mar 2026 | $29.07M | +39.8% | +15.8% | 71.6% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Jun 2024 | $21.25M | — | +111.9% | 31.7% |
| LTM Mar 2026 | $14.21M | +21.8% | -0.1% | 13535.2% | |
| LTM Mar 2026 | $10.03M | -33.1% | +55.7% | 20.7% | |
| Peer median (excluding PRCT) | $17.73M | +21.8% | +35.8% | 51.6% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| Deferred Income Tax | 451K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.8M | 10.34M | 19.13M | 31.84M | 47.6M |
| Change in Working Capital | (4.71M) | (11.49M) | (26.16M) | (47.33M) | (7.84M) |
| Accounts Receivables | (2.91M) | (10.81M) | (33.1M) | (35.96M) | (898K) |
| Inventory | (6.12M) | (15.25M) | (9.75M) | (17.24M) | (14.5M) |
| Accounts Payables | 812K | 3.96M | 5.79M | (2.15M) | 6.65M |
| Other Working Capital | 3.52M | 10.61M | 10.9M | 8.02M | 909K |
| Other Non-Cash Items | (345K) | 5.08M | 1.12M | 2.45M | 433K |
| Operating Cash Flow | (57.33M) | (80.38M) | (108M) | (99.21M) | (48.99M) |
| Capital Expenditures | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Debt Repayment | 0 | 1.2M | 0 | 0 | 0 |
| Common Stock Issued | 172.36M | 0 | 161.71M | 164.52M | 11.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.04M | 2.42M | 6.09M | 15.6M | 0 |
| Financing Cash Flow | 262.12M | 3.61M | 167.8M | 180.13M | 11.19M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (74K) |
| Net Change in Cash | 204.19M | (79.42M) | 34.59M | 76.5M | (47.22M) |
| Free Cash Flow | (57.93M) | (83.04M) | (133.21M) | (103.62M) | (58.34M) |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.